These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22801952)

  • 1. Sclerostin: a candidate biomarker of SCI-induced osteoporosis.
    Morse LR; Sudhakar S; Lazzari AA; Tun C; Garshick E; Zafonte R; Battaglino RA
    Osteoporos Int; 2013 Mar; 24(3):961-8. PubMed ID: 22801952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between sclerostin and bone density in chronic spinal cord injury.
    Morse LR; Sudhakar S; Danilack V; Tun C; Lazzari A; Gagnon DR; Garshick E; Battaglino RA
    J Bone Miner Res; 2012 Feb; 27(2):352-9. PubMed ID: 22006831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating sclerostin is elevated in short-term and reduced in long-term SCI.
    Battaglino RA; Sudhakar S; Lazzari AA; Garshick E; Zafonte R; Morse LR
    Bone; 2012 Sep; 51(3):600-5. PubMed ID: 22575440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults.
    Coulson J; Bagley L; Barnouin Y; Bradburn S; Butler-Browne G; Gapeyeva H; Hogrel JY; Maden-Wilkinson T; Maier AB; Meskers C; Murgatroyd C; Narici M; Pääsuke M; Sassano L; Sipilä S; Al-Shanti N; Stenroth L; Jones DA; McPhee JS
    Osteoporos Int; 2017 Sep; 28(9):2683-2689. PubMed ID: 28585053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Periostin and sclerostin levels in individuals with spinal cord injury and their relationship with bone mass, bone turnover, fracture and osteoporosis status.
    Maïmoun L; Ben Bouallègue F; Gelis A; Aouinti S; Mura T; Philibert P; Souberbielle JC; Piketty M; Garnero P; Mariano-Goulart D; Fattal C
    Bone; 2019 Oct; 127():612-619. PubMed ID: 31351195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
    Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis.
    Klingberg E; Nurkkala M; Carlsten H; Forsblad-d'Elia H
    J Rheumatol; 2014 Jul; 41(7):1349-56. PubMed ID: 24931960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sclerostin Antibody Reverses the Severe Sublesional Bone Loss in Rats After Chronic Spinal Cord Injury.
    Zhao W; Li X; Peng Y; Qin Y; Pan J; Li J; Xu A; Ominsky MS; Cardozo C; Feng JQ; Ke HZ; Bauman WA; Qin W
    Calcif Tissue Int; 2018 Oct; 103(4):443-454. PubMed ID: 29931461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
    Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
    Voskaridou E; Christoulas D; Plata E; Bratengeier C; Anastasilakis AD; Komninaka V; Kaliontzi D; Gkotzamanidou M; Polyzos SA; Dimopoulou M; Terpos E
    Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of serum myostatin and sclerostin levels in chronic spinal cord injured patients.
    Invernizzi M; Carda S; Rizzi M; Grana E; Squarzanti DF; Cisari C; Molinari C; Renò F
    Spinal Cord; 2015 Aug; 53(8):615-20. PubMed ID: 25896346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of serum sclerostin with bone mineral density, markers of bone metabolism and thalassaemia characteristics in adult patients with transfusion-dependent beta-thalassaemia.
    Sapunarova K; Goranova-Marinova V; Georgiev P; Deneva T; Tsvetkova S; Grudeva-Popova Z
    Ann Med; 2020; 52(3-4):94-108. PubMed ID: 32212941
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
    Polyzos SA; Anastasilakis AD; Bratengeier C; Woloszczuk W; Papatheodorou A; Terpos E
    Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mice with sclerostin gene deletion are resistant to the severe sublesional bone loss induced by spinal cord injury.
    Qin W; Zhao W; Li X; Peng Y; Harlow LM; Li J; Qin Y; Pan J; Wu Y; Ran L; Ke HZ; Cardozo CP; Bauman WA
    Osteoporos Int; 2016 Dec; 27(12):3627-3636. PubMed ID: 27436301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sclerostin inhibition prevents spinal cord injury-induced cancellous bone loss.
    Beggs LA; Ye F; Ghosh P; Beck DT; Conover CF; Balaez A; Miller JR; Phillips EG; Zheng N; Williams AA; Aguirre JI; Wronski TJ; Bose PK; Borst SE; Yarrow JF
    J Bone Miner Res; 2015 Apr; 30(4):681-9. PubMed ID: 25359699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spinal cord injury-induced osteoporosis: pathogenesis and emerging therapies.
    Battaglino RA; Lazzari AA; Garshick E; Morse LR
    Curr Osteoporos Rep; 2012 Dec; 10(4):278-85. PubMed ID: 22983921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for the development of osteoporosis after spinal cord injury. A 12-month follow-up study.
    Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2015 Sep; 26(9):2273-80. PubMed ID: 25939310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of low intensity vibration on bone and muscle in rats with spinal cord injury.
    Bramlett HM; Dietrich WD; Marcillo A; Mawhinney LJ; Furones-Alonso O; Bregy A; Peng Y; Wu Y; Pan J; Wang J; Guo XE; Bauman WA; Cardozo C; Qin W
    Osteoporos Int; 2014 Sep; 25(9):2209-19. PubMed ID: 24861907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis.
    Taylan A; Sari I; Akinci B; Bilge S; Kozaci D; Akar S; Colak A; Yalcin H; Gunay N; Akkoc N
    BMC Musculoskelet Disord; 2012 Oct; 13():191. PubMed ID: 23025387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
    Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2016 Jan; 27(1):405-10. PubMed ID: 26423406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.